Xue P, Wu Z, Wang K, et al. - Whether a multimodal approach including local primary tumor therapy, metastasis-directed therapy (MDT), and hormonal therapy, has efficacy and safety in patients with oligometastatic prostate cancer (PCa) was assessed in this multi-center, retrospective cohort study. There were 58 patients, in whom, the 3-year castration-resistant prostate cancer (CRPC)-free survival and cancer-specific survival was found to be 75.9% and 91.4%, respectively. In subgroup analysis, significantly better CRPC-free survival was experienced by the MDT group vs the non-MDT group with Gleason grade groups 1– 4. Overall, findings showed that combining cytoreductive prostatectomy and metastasis-directed radiotherapy for newly-diagnosed oligometastatic PCa is a feasible treatment approach that has the potential to delay the progression to CRPC.